ANGUS Unveils a New Division: ANGUS Life Sciences

ANGUS Life Sciences to serve pharmaceutical, biotechnology and agriculture markets

BUFFALO GROVE, Ill. – MARCH 14 2016 - ANGUS Chemical Company, a leading manufacturer and marketer of nitroalkanes and their derivatives, today announced the launch of its new life sciences division, ANGUS Life Sciences. Formed to provide a dedicated focus on the specific needs of the life sciences industry, ANGUS Life Sciences supplies customers in the biotechnology, pharmaceutical and agriculture markets with the high-quality buffers, biochemicals, biomolecules and intermediates they have come to rely on.

“Our new ANGUS Life Sciences division is built on our rich, 70-year legacy of manufacturing specialized chemistries, such as our TRIS AMINO®,” said Mark Henning, President and CEO of ANGUS. “We understand the importance of aligning and controlling stability, consistency, quality and compliance across the duration of product lifecycles. This new business division is a testament to our commitment to our life sciences customers by providing premium fine and specialty chemistries they need to develop their best products for R&D, scale-up and production.”

Based in the United States, ANGUS Life Sciences is the world’s only fully integrated manufacturer of TRIS AMINO buffers, based on their unique nitroalkane chemistry. In addition to TRIS AMINO, ANGUS Life Sciences also provides other high-quality offerings, including biological buffers, biochemicals, biomolecules and amino acids.

“We’re dedicated to what matters most to our customers – quality products, traceable and auditable supply chains, and optimized cost-effectiveness and efficiency. Through ANGUS Life Sciences, we strive to be an innovative partner to our customers within the life sciences industry,” said Dave Green, Vice President of R&D at ANGUS. “We look forward to helping our customers develop winning products, conduct successful launches and achieve faster time-to-market.”

Customer-specific testing, packaging and labeling are also available through ANGUS Life Sciences, whose facilities are cGMP compliant and ISO 9001:2008 certified.

For more information, please visit ANGUS Life Sciences.



About ANGUS Chemical Company

ANGUS Chemical Company (“ANGUS”) is a specialty and fine chemical company dedicated to the development of novel chemistry that helps customers deliver enhanced product and process performance. ANGUS is committed to constantly improving products and services by mastering science and technology. The company innovates through its unique nitroalkane chemistry, which harbors the reactivity to create complex molecules for use in a wide variety of applications. The innate characteristics of this chemistry enable multifunctional additives which improve performance, reduce reaction steps and cut synthesis costs.


About Golden Gate Capital

Golden Gate Capital is a San Francisco-based private equity investment firm with approximately $12 billion of capital under management. Golden Gate Capital is dedicated to partnering with world-class management teams to invest in change-intensive, growth businesses. The firm targets investments where there is a demonstrable opportunity to significantly enhance a company’s value. The principals of Golden Gate Capital have a long and successful history of investing with management partners across a wide range of industries and transaction types. Other notable mining and industrials investments sponsored by Golden Gate Capital include US Silica, EP Minerals, ArrMaz, Humanetics Innovative Solutions, Springs Window Fashions, Canada Fluorspar Inc. and Atrium Windows. For more information, visit www.goldengatecap.com.


Media for ANGUS Chemical Company:

Scott C. Johnson
+1 847-808-3769
scjohnson@angus.com


Media for Golden Gate Capital:

Sard Verbinnen & Co
Nathaniel Garnick / Jenny Gore
212-687-8080 / 312-895-4700